Hologic hoists Q3 top-line by 33% but lowers Q4/FY outlook
This article was originally published in Clinica
Women’s health specialist Hologic is still reaping the rewards of its $3.7bn acquisition of Gen-Probe, after it posted high double-digit growth for yet another quarter. Hologic attributed the 33% increase in its third fiscal quarter revenue, at $626.1m, to the inclusion of revenue from the molecular diagnostics business which it acquired in May 2012 (www.clinica.co.uk, 1 May 2012).
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.